

RESEARCH LETTER

Fluorine-19 Magnetic Resonance Imaging of Activated Platelets

Xiaowei Wang , PhD*; Sebastian Temme , PhD*; Christoph Grapentin, PhD; Jathushan Palasubramaniam, MBBS; Aidan Walsh, BSc (Hons); Wolfgang Krämer, PhD; Patricia Kleimann, BSc; Asli Havlas, MSc; Rolf Schubert, PhD; Jürgen Schrader, MD; Ulrich Flögel , PhD†; Karlheinz Peter , MD, PhD†

The central role of platelets in thrombosis is well characterized. Recently, evidence has emerged that platelets also play crucial roles in inflammation and cancer. Therefore, reliable and sensitive imaging of activated platelets holds promise to improve diagnosis in numerous diseases and addresses a significant clinical need.¹ Here, we describe an innovative method for imaging activated platelets using advanced fluorine-19 (¹⁹F) magnetic resonance imaging (MRI).

MRI provides high-resolution imaging, even in deep tissues, without harmful ionizing radiation. Visualization of thrombi, inflammation, early cancer, and metastases is difficult since these structures are often not well differentiated against surrounding tissues. MRI contrast based on gadolinium or iron oxide has been employed to improve tissue differentiation. However, these contrast agents are imaged using conventional hydrogen (¹H)-based MRI and are sometimes difficult to differentiate from anatomical structure. An alternative, ¹⁹F-based MRI holds promise for greater specificity. ¹⁹F is essentially absent from biological tissue, allowing for background-free localization. The merge of ¹H and ¹⁹F data sets allows for exact anatomical localization and molecular characterization. Furthermore, the linear relationship between fluorine concentration and signal intensity permits direct quantification of contrast agent accumulation.

¹⁹F MRI contrast agents are typically generated using perfluorocarbons, which are chemically and biologically inert, rendering them safe for in vivo use.²

Perfluorocarbons are emulsified with phospholipids to form stable, biocompatible, and intravenously administrable nanoemulsions (PFCs). Non-conjugated PFCs are phagocytosed by monocytes/macrophages, a method utilized for imaging of inflammation in mouse models of myocardial and cerebral ischemia, myocarditis, and pneumonia.¹ Direct targeting of PFCs, independent of phagocytosis, using small antiplasmin peptide-conjugated PFCs were successfully employed to detect the early phase of venous thrombosis via ¹⁹F MRI.³

To achieve selective targeting of activated platelets, we chose to target the activated conformation of integrin glycoprotein IIb/IIIa (GPIIb/IIIa; $\alpha_{IIb}\beta_3$, CD41/CD61). GPIIb/IIIa is highly specific for platelets and is the most abundantly expressed receptor on the platelet surface ($\approx 60\ 000$ receptors per platelet). Upon platelet activation, GPIIb/IIIa undergoes a conformational change with the selective exposure of specific epitopes.⁴ We generated a unique human single-chain antibody (scFv), that binds specifically to the activated conformation of GPIIb/IIIa (scFv^{Targ}), and exhibits the same binding profile on human and mouse platelets, providing a distinct advantage for cross-species testing.^{4,5} The scFv^{Targ} does not bind to nonactivated circulating platelets or to other proteins or cells in the blood.⁴ This scFv^{Targ} has been successfully used for molecular imaging of diseases across a range of imaging technologies, including ultrasound, positron emission tomography,

Key Words: Fluorine-19 MRI ■ activated platelet targeting ■ molecular imaging ■ platelets ■ thrombosis

Correspondence to: Karlheinz Peter, MD, PhD, and Xiaowei Wang, PhD, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, 3004 Victoria, Australia. E-mail: karlheinz.peter@baker.edu.au, xiaowei.wang@baker.edu.au

*Dr Wang and Dr Temme contributed equally to this work as co-first authors.

†Dr Flögel and Dr Peter contributed equally to this work as co-senior authors.

For Sources of Funding and Disclosures, see page 3.

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

Figure. Flourine-19 (¹⁹F) magnetic resonance imaging (MRI) of thrombosis by targeting to the activated form of glycoprotein IIb/IIIa on platelets.

A, Representative microscopy images demonstrate the successful attachment of FITC-labeled targeted perfluorocarbon nanoemulsions (^{Targ}PFCs) to microthrombi in a flow-chamber adhesion assay, generated with human blood. **B,** Quantification of fluorescence intensity demonstrates a significant increase in intensity for ^{Targ}PFCs (red) binding to human microthrombi, as compared with non-targeted PFCs (^{Non-targ}PFCs; blue) and non-conjugated PFCs (white; PFCs only) (***P*<0.001). **C,** In vitro formation of human thrombi demonstrates targeting of ^{Targ}PFCs using fluorescence imaging on in vivo imaging system (IVIS). **D,** Quantification of IVIS fluorescence intensity of rhodamine on perfluorocarbons (***P*<0.01; **P*<0.05). **E,** In vitro formation of thrombi demonstrates targeting of ^{Targ}PFCs using ¹⁹F MRI. **F,** In vivo imaging of activated platelets using ^{Targ}PFCs in a mouse model of ferric chloride-induced thrombosis of the inferior vena cava (IVC); red arrows indicate the location of thrombi, with representative MRI (hydrogen [¹H] and ¹⁹F) images of thrombi in the IVC using ^{Targ}PFCs (upper) or ^{Non-targ}PFCs (lower). **G,** A significant increase in the ¹⁹F signal was observed for ^{Targ}PFCs, as compared with ^{Non-targ}PFCs, for signal-to-noise ratio (***P*<0.001). Male C57Bl/6J mice (20–25 g), sourced from the ZETT (central animal facility) of the Heinrich Heine University (Düsseldorf, Germany), were randomized into different experimental groups and thrombosis was then induced surgically in the IVC. All procedures for animal studies were performed in accordance with institutional guidelines. PFCs injected intravenously 15 minutes post injury and ¹⁹F MRI was performed immediately post administration. Assays with 2 groups were analyzed using unpaired *t* test, and all assays with ≥3 groups were analyzed with 1-way ANOVA followed by the Bonferroni post hoc test.

human blood^{4,5} (Figure—Panels A and B). ^{Targ}PFCs displayed significantly increased binding to microthrombi compared with ^{Non-targ}PFCs and unmodified PFCs (39.0 versus 4.2 versus 3.5 fluorescence intensity, respectively; *n*=15, *P*<0.05). Additionally, we incubated in vitro-generated human thrombi with ^{Targ}PFCs and ^{Non-targ}PFCs, followed by imaging via an in vivo imaging system and ¹⁹F MRI (Figure—Panels C through E). Thrombi exposed to ^{Targ}PFCs displayed a significantly increased fluorescence intensity, as well as ¹⁹F signal (907 versus 389 versus 478 fluorescence intensity, respectively; *n*=6, *P*<0.05).

To explore the feasibility of imaging activated platelets in vivo, we used a murine model of ferric chloride-induced thrombosis of the inferior vena cava (Figure—Panels F and G). Male C57Bl/6J mice (20–25 g), sourced from the ZETT (central animal facility) of the Heinrich Heine University (Düsseldorf, Germany), were randomized into different experimental groups. All procedures for animal studies were performed in accordance with institutional guidelines. Perfluorocarbons (1 μg/g of body weight) were injected 15 minutes post injury and ¹⁹F MRI was conducted immediately. Intravenous administration of ^{Targ}PFCs revealed a strong, background-free ¹⁹F MRI signal at the thrombus, whereas injection of ^{Non-targ}PFCs showed only a low background signal (9.4 versus 1.8 signal-to-noise ratio, *P*<0.001). Injection of ^{Targ}PFCs led to significantly increased ¹⁹F MRI intensity compared with ^{Non-targ}PFCs (8×10⁵ versus 2.4×10⁵ intensity, *P*<0.001).

Overall, our data demonstrate that ^{Targ}PFCs are an ideal contrast agent for background-free molecular ¹⁹F MRI of activated platelets, in both humans and mice. ^{Targ}PFCs bind specifically to activated GPIIb/IIIa receptors in vitro and in vivo; therefore, they only accumulate at sites of platelet activation. Early diagnosis of diseases characterized by involvement of activated platelets, such as thrombotic, atherosclerotic, inflammatory, and malignant diseases, facilitates early therapeutic intervention and ultimately improves outcomes for patients. While this is a proof-of-concept study, the

use of well-tolerated PFCs and low-antigenicity human scFvs, along with background-free ¹⁹F MRI, strongly supports the translational prospect of early diagnosis of numerous diseases with a potentially broad health impact.

ARTICLE INFORMATION

Received May 29, 2020; accepted July 28, 2020.

Affiliations

From the Atherothrombosis and Vascular Biology Laboratory (X.W., J.P., A.W., K.P.) and Molecular Imaging and Theranostics Laboratory (X.W., J.P., A.W.), Baker Heart and Diabetes Institute, Melbourne, Australia; Department of Medicine, Monash University, Melbourne, Australia (X.W., J.P., A.W., K.P.); Experimental Cardiovascular Imaging, Department of Molecular Cardiology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany (S.T., P.K., A.H., J.S., U.F.); and Institute for Pharmaceutical Sciences, University of Freiburg, Germany (C.G., W.K., R.S.).

Sources of Funding

This work was funded by the Australian National Health and Medical Research Council (NHMRC; project grant 1108670) and in part by the Victorian Government Operational Infrastructure Support Program. In addition, Wang is supported by a National Heart Foundation Future Leader Fellowship, Baker Fellowship, and AMP Tomorrow Maker Fund. Palasubramaniam and Walsh are supported by Monash University Scholarships. Palasubramaniam is also supported by an NHRMC Postgraduate Scholarship. Peter is supported by an NHMRC Investigator Fellowship. The work was also supported by grants from the Deutsche Forschungsgemeinschaft TE1209/1-1 (Temme, Kleimann, Havlas), FL303/6-1 (Flögel), SCHU 800/8-2 (Grapentin), SFB 1116 (Temme, Flögel), and European grants NOVA MRI (Temme, Flögel, Schrader) and PRISAR2 (Temme, Flögel).

Disclosures

Wang and Peter are inventors on patents describing activated platelet-targeting recombinant antibodies.

REFERENCES

1. Wang X, Peter K. Molecular imaging of atherothrombotic diseases: seeing is believing. *Arterioscler Thromb Vasc Biol.* 2017;37:1029–1040.
2. Schmieder AH, Caruthers SD, Keupp J, Wickline SA, Lanza GM. Recent advances in 19fluorine magnetic resonance imaging with perfluorocarbon emulsions. *Engineering.* 2015;1:475–489.
3. Temme S, Grapentin C, Quast C, Jacoby C, Grandoch M, Ding Z, Owenier C, Mayenfels F, Fischer JW, Schubert R, et al. Non-invasive imaging of early venous thrombosis by 19F magnetic resonance imaging with targeted perfluorocarbon nanoemulsions. *Circulation.* 2015;131:1405–1414.

-
4. Wang X, Hagemeyer CE, Hohmann JD, Leitner E, Armstrong PC, Jia F, Olschewski M, Needles A, Peter K, Ahrens I. Novel single-chain antibody-targeted microbubbles for molecular ultrasound imaging of thrombosis: validation of a unique non-invasive method for rapid and sensitive detection of thrombi and monitoring of success or failure of thrombolysis in mice. *Circulation*. 2012;125:3117–3126.
 5. von Elverfeldt D, Maier A, Duerschmied D, Braig M, Witsch T, Wang X, Mauler M, Neudorfer I, Menza M, Idzko M, et al. Dual-contrast molecular imaging allows non-invasive characterization of myocardial ischemia/reperfusion injury after coronary vessel occlusion in mice by magnetic resonance imaging. *Circulation*. 2014;130:676–687.